Price Chart

Profile

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
URL https://www.vcel.com
Investor Relations URL https://investors.vcel.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release May. 10, 2024 (est.)
Last Earnings Release Feb. 29, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
URL https://www.vcel.com
Investor Relations URL https://investors.vcel.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release May. 10, 2024 (est.)
Last Earnings Release Feb. 29, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A